Abstract
..
Main
..
RCT vs. Obs.
..
Feedback
Home
c19early.org COVID-19 treatment researchConvalescent PlasmaConv. Plasma (more..)
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta
Ivermectin Meta
Thermotherapy Meta
Melatonin Meta
Metformin Meta
Home Adoption Other Treatments
@CovidAnalysis
Loading...
 
Analgesics⏵
Antiandrogens⏵
Antihistamines⏵
Budesonide
Colchicine
Conv. Plasma
Curcumin
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle⏵
Melatonin
Metformin
Minerals⏵
Monoclonals⏵
Mpro inhibitors⏵
Naso/orophar..⏵
Nigella Sativa
Nitazoxanide
PPIs
Quercetin
RdRp inhibitors⏵
TMPRSS2 inh.⏵
Thermotherapy
Vitamins⏵
More⏵
 

Supplementary Data — Convalescent Plasma for COVID-19: real-time meta analysis of 57 studies

@CovidAnalysis, June 2025, Version 44V44
PDF
All
Studies
All
Treatments
Feedback
https://c19early.org/cpmeta.html
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ INFANT-COVID-19 Libster (DB RCT) 50% 0.50 [0.09-2.65] death 2/80 4/80 Improvement, RR [CI] Treatment Control INFANT-COVID-19 Libster (DB RCT) 50% 0.50 [0.09-2.65] ventilation 2/80 4/80 INFANT-COVID-19 Libster (DB RCT) 67% 0.33 [0.07-1.60] ICU 2/80 6/80 INFANT-COVID-19 Libster (DB RCT) 48% 0.52 [0.29-0.94] progression 13/80 25/80 Balcells (RCT) -247% 3.47 [0.35-11.9] death 5/28 2/30 Balcells (RCT) -163% 2.63 [0.43-9.10] ventilation 5/28 2/30 Balcells (RCT) -23% 1.23 [0.56-1.89] progression 13/28 12/30 Van Hise (RCT) -441% 5.41 [0.29-101] hosp. 3/49 0/23 C3PO Korley (RCT) -396% 4.96 [0.58-42.2] death 5/250 1/248 C3PO Korley (RCT) 10% 0.90 [0.64-1.26] hosp. 51/257 56/254 C3PO Korley (RCT) 6% 0.94 [0.72-1.22] progression 77/257 81/254 CONV-ERT Alemany (DB RCT) 80% 0.20 [0.01-4.14] death 0/188 2/188 CONV-ERT Alemany (DB RCT) -5% 1.05 [0.60-1.84] hosp. 22/188 21/188 CONV-ERT Alemany (DB RCT) -5% 1.05 [0.85-1.30] no recov. 188 (n) 188 (n) CONV-ERT Alemany (DB RCT) -4% 1.04 [0.97-1.11] viral load 188 (n) 188 (n) CONV-ERT Alemany (DB RCT) 4% 0.96 [0.88-1.05] viral load 188 (n) 188 (n) CoV-Early Gharbharan (DB RCT) -1% 1.01 [0.06-16.0] death 1/207 1/209 CoV-Early Gharbharan (DB RCT) 67% 0.33 [0.01-8.16] ventilation 0/207 1/209 CoV-Early Gharbharan (DB RCT) 14% 0.86 [0.59-1.22] progression 207 (n) 209 (n) CoV-Early Gharbharan (DB RCT) 42% 0.58 [0.33-1.02] progression 123 (n) 103 (n) CoV-Early Gharbharan (DB RCT) 39% 0.61 [0.28-1.34] hosp. 10/207 18/209 CoV-Early Gharbharan (DB RCT) -50% 1.50 [0.40-5.64] hosp. time 207 (n) 209 (n) CoV-Early Gharbharan (DB RCT) -1% 1.01 [0.88-1.16] no recov. 137/207 137/209 CoV-Early Gharbharan (DB RCT) -8% 1.1 [0.00-9e+04] recov. time 207 (n) 209 (n) COVIC-19 Hoffmann (RCT) 51% 0.49 [0.05-5.27] death 1/59 2/58 COVIC-19 Hoffmann (RCT) 91% 0.09 [0.01-0.77] death/hosp. 0/59 5/58 COVIC-19 Hoffmann (RCT) 89% 0.11 [0.01-2.00] death/hosp. 0/59 4/58 COVIC-19 Hoffmann (RCT) 67% 0.33 [0.01-7.97] ICU 0/59 1/58 Li (RCT) 35% 0.65 [0.27-1.39] death 8/51 12/50 Li (RCT) 15% 0.85 [0.53-1.18] no improv. 25/52 29/51 Li (RCT) 76% 0.24 [0.07-0.64] viral+ 4/26 15/23 ConPlas-19 Avendaño-Solà (RCT) 88% 0.12 [0.01-2.11] death 0/38 4/43 ConPlas-19 Avendaño-Solà (RCT) 93% 0.07 [0.01-0.57] progression 0/38 7/43 ConPlas-19 Avendaño-Solà (RCT) 92% 0.08 [0.01-0.76] progression 0/38 6/43 PLACID Agarwal (RCT) -7% 1.07 [0.73-1.58] death 34/235 31/229 PLACID Agarwal (RCT) -7% 1.07 [0.73-1.58] progression 44/235 41/229 PLACID Agarwal (RCT) 1% 0.99 [0.54-1.81] ventilation 19/227 19/224 PLACID Agarwal (RCT) 28% 0.72 [0.55-0.95] viral+ 56/173 76/169 ILBS-COVID-02 Bajpai (RCT) -323% 4.23 [0.43-41.6] death 3/14 1/15 ILBS-COVID-02 Bajpai (RCT) -114% 2.14 [0.22-21.1] death 2/14 1/15 ILBS-COVID-02 Bajpai (RCT) -221% 3.21 [0.38-27.4] ventilation 3/14 1/15 ILBS-COVID-02 Bajpai (RCT) 25% 0.75 [0.54-1.04] hosp. time 14 (n) 15 (n) ILBS-COVID-02 Bajpai (RCT) 33% 0.67 [0.41-1.10] viral load 14 (n) 15 (n) AlQahtani (RCT) 50% 0.50 [0.05-5.08] death 1/20 2/20 AlQahtani (RCT) 33% 0.67 [0.22-2.01] ventilation 4/20 6/20 AlQahtani (RCT) 22% 0.78 [0.57-1.07] hosp. time 20 (n) 20 (n) PlasmAr Simonovich (RCT) 4% 0.96 [0.50-1.83] death 25/228 12/105 PlasmAr Simonovich (RCT) 19% 0.81 [0.50-1.31] 7-point status 228 (n) 105 (n) Ray (RCT) 33% 0.67 [0.30-1.50] death 10/40 14/40 RECOVERY Recovery Co.. (RCT) 0% 1.00 [0.93-1.07] death 1,399/5,795 1,408/5,763 RECOVERY Recovery Co.. (RCT) -1% 1.01 [0.97-1.06] no disch. 1,963/5,795 1,941/5,763 Gonzalez -7% 1.07 [0.76-1.50] death 60/130 26/60 OT​1​ Gonzalez -1% 1.01 [0.76-1.34] death 70/130 32/60 OT​1​ Pouladza.. (SB RCT) 40% 0.60 [0.16-2.29] death 3/30 5/30 Pouladza.. (SB RCT) -30% 1.30 [0.99-1.71] hosp. time 30 (n) 30 (n) Bennett-.. (DB RCT) 19% 0.81 [0.36-1.86] death 16/59 5/15 Bennett-.. (DB RCT) 11% 0.89 [0.34-2.31] death 14/59 4/15 Bennett-.. (DB RCT) 0% 1.00 [0.75-1.32] no improv. 47/59 12/15 Elhadi (ICU) -16% 1.16 [0.88-1.54] death 16/23 265/442 ICU patients LIFESAVER Teofili (RCT) -100% 2.00 [0.16-24.3] death 1/4 1/8 ConCoVid-19 Gharbharan (RCT) 4% 0.96 [0.25-2.41] death 6/43 11/43 ConCoVid-19 Gharbharan (RCT) 12% 0.88 [0.49-1.60] no disch. 43 (n) 43 (n) Cho -4% 1.04 [0.64-1.62] death 402 (n) 4,642 (n) PLACOVID Sekine (RCT) -38% 1.38 [0.73-2.63] death 18/80 13/80 PLACOVID Sekine (RCT) -100% 2.00 [0.72-5.59] death 10/80 5/80 PLACOVID Sekine (RCT) -11% 1.11 [0.74-1.66] no improv. 31/80 28/80 PLACOVID Sekine (RCT) -67% 1.67 [0.01-470] hosp. time 80 (n) 80 (n) COVIDIT Kirenga (RCT) -21% 1.21 [0.51-2.89] death 10/69 8/67 COVIDIT Kirenga (RCT) 9% 0.91 [0.38-2.16] progression 9/41 7/29 COVIDIT Kirenga (RCT) -50% 1.50 [0.81-2.77] viral time 67 (n) 67 (n) CAPRI Hsue (DB RCT) -212% 3.12 [0.14-71.7] death 1/16 0/18 CAPRI Hsue (DB RCT) -12% 1.12 [0.08-16.6] death 1/16 1/18 CAPRI Hsue (DB RCT) -425% 5.25 [0.27-102] ventilation 2/16 0/18 CAPRI Hsue (DB RCT) -425% 5.25 [0.27-102] progression 2/16 0/18 CAPRI Hsue (DB RCT) -425% 5.25 [0.27-102] progression 2/16 0/18 DAWn-plasma Devos (RCT) 1% 0.99 [0.52-1.88] death 320 (n) 163 (n) DAWn-plasma Devos (RCT) -8% 1.08 [0.65-1.80] ventilation 320 (n) 163 (n) DAWn-plasma Devos (RCT) 0% 1.00 [0.74-1.34] ICU 320 (n) 163 (n) CONCOR-1 Bégin (RCT) -13% 1.13 [0.88-1.45] death 156/625 69/313 CONCOR-1 Bégin (RCT) -12% 1.12 [0.86-1.46] death 141/614 63/307 CONCOR-1 Bégin (RCT) -16% 1.16 [0.94-1.43] death/int. 199/614 86/307 CAPSID Körper (RCT) 37% 0.63 [0.33-1.22] death 11/53 17/52 CAPSID Körper (RCT) 14% 0.86 [0.34-2.20] death 7/53 8/52 CAPSID Körper (RCT) 16% 0.84 [0.62-1.14] no recov. 30/53 35/52 LACCPT Abayomi (DB RCT) -17% 1.17 [0.58-2.35] death 7/11 6/11 TSUNAMI Menichetti (RCT) 23% 0.77 [0.39-1.49] death 14/231 19/240 TSUNAMI Menichetti (RCT) -4% 1.04 [0.62-1.75] ventilation 25/231 25/240 TSUNAMI Menichetti (RCT) 12% 0.88 [0.59-1.33] progression 59/231 67/239 COP20 Holm (RCT) 45% 0.55 [0.11-2.84] death 2/17 3/14 COP20 Holm (RCT) 69% 0.31 [0.01-7.09] ventilation 0/17 1/14 COP20 Holm (RCT) 19% 0.81 [0.25-2.64] progression 4/16 4/13 COP20 Holm (RCT) -57% 1.57 [0.52-4.74] oxygen time 17 (n) 14 (n) COP20 Holm (RCT) -62% 1.62 [0.76-3.46] hosp. time 17 (n) 14 (n) CONTAIN COVID-19 Ortigoza (DB RCT) 12% 0.88 [0.63-1.20] death 59/462 71/462 CONTAIN COVID-19 Ortigoza (DB RCT) 1% 0.99 [0.66-1.47] death 35/463 39/463 CONTAIN COVID-19 Ortigoza (DB RCT) 8% 0.92 [0.74-1.16] WHO scale 468 (n) 473 (n) CONTAIN COVID-19 Ortigoza (DB RCT) 6% 0.94 [0.75-1.18] WHO scale 468 (n) 473 (n) CONTAIN COVID-19 Ortigoza (DB RCT) -2% 1.02 [0.77-1.37] PASC 141 (n) 140 (n) CONTAIN COVID-19 Ortigoza (DB RCT) 5% 0.95 [0.54-1.67] PASC 141 (n) 140 (n) CONTAIN COVID-19 Ortigoza (DB RCT) -15% 1.15 [0.59-2.25] PASC 141 (n) 140 (n) CONTAIN COVID-19 Ortigoza (DB RCT) 18% 0.82 [0.44-1.51] PASC 141 (n) 140 (n) CONTAIN COVID-19 Ortigoza (DB RCT) -18% 1.18 [0.71-1.95] PASC 141 (n) 140 (n) PennCCP2 Bar (RCT) 81% 0.19 [0.04-0.84] death 40 (n) 39 (n) PennCCP2 Bar (RCT) 44% 0.56 [0.24-1.29] no improv. 40 (n) 39 (n) PennCCP2 Bar (RCT) 51% 0.49 [0.18-1.30] ventilation 5/40 10/39 CSSC-004 Sullivan (DB RCT) 86% 0.14 [0.01-2.75] death 0/592 3/589 CSSC-004 Sullivan (DB RCT) 25% 0.75 [0.17-3.32] ICU 3/592 4/589 CSSC-004 Sullivan (DB RCT) 54% 0.46 [0.26-0.80] hosp. 17/592 37/589 Jalili (RCT) -45% 1.45 [0.74-2.87] death 16/60 11/60 Jalili (RCT) -8% 1.08 [0.72-1.63] ICU 27/60 25/60 Jalili (RCT) -250% 3.50 [0.76-16.2] ARDS 7/60 2/60 Jalili (RCT) -10% 1.10 [0.89-1.36] hosp. time 60 (n) 60 (n) Baldeón (DB RCT) 12% 0.88 [0.37-2.11] death 7/63 12/95 PROTECT-Patient van den Berg (RCT) 17% 0.83 [0.41-1.68] death 11/52 13/51 PROTECT-Patient van den Berg (RCT) 67% 0.33 [0.04-3.04] ventilation 1/52 3/51 PROTECT-Patient van den Berg (RCT) 5% 0.95 [0.55-1.63] no improv. 16/47 18/50 PROTECT-Patient van den Berg (RCT) -3% 1.03 [0.62-1.71] no disch. 18/46 19/50 Mesina -29% 1.29 [0.70-2.36] death 18/65 14/65 Mesina -60% 1.60 [0.96-2.65] hosp. time 65 (n) 65 (n) De Santis (RCT) 13% 0.87 [0.48-1.56] death 11/36 25/71 De Santis (RCT) 12% 0.88 [0.42-1.82] death 8/36 18/71 COPLA-II Bajpai (RCT) -14% 1.14 [0.76-1.69] death 42/200 37/200 COPLA-II Bajpai (RCT) -19% 1.19 [0.69-2.06] death 25/200 21/200 COPLA-II Bajpai (RCT) -12% 1.12 [0.67-1.88] ventilation 27/200 24/200 COPLA-II Bajpai (RCT) -2% 1.02 [0.90-1.15] ICU 200 (n) 200 (n) COPLA-II Bajpai (RCT) 0% 1.00 [0.91-1.09] hosp. time 200 (n) 200 (n) COPLA-II Bajpai (RCT) 6% 0.94 [0.71-1.24] no recov. 64/200 68/200 COPLA-II Bajpai (RCT) -1% 1.01 [0.98-1.05] viral+ 200 (n) 200 (n) CP-COVID-19 Rojas (SB RCT) -220% 3.20 [0.64-16.0] death 46 (n) 45 (n) CP-COVID-19 Rojas (SB RCT) 38% 0.62 [0.40-0.97] no disch. 46 (n) 45 (n) CP-COVID-19 Rojas (SB RCT) -25% 1.25 [0.36-4.33] viral+ 46 (n) 45 (n) CP-COVID-19 Rojas (SB RCT) -16% 1.16 [0.33-4.08] viral+ 46 (n) 45 (n) CP-COVID-19 Rojas (SB RCT) -51% 1.51 [0.33-6.98] viral+ 46 (n) 45 (n) CP-COVID-19 Rojas (SB RCT) -12% 1.12 [0.16-7.84] viral+ 46 (n) 45 (n) COOP-COVID-19-MCTI Song (RCT) -52% 1.52 [0.70-3.27] death 22/87 7/42 CORIPLASM Lacombe (RCT) 49% 0.51 [0.20-1.32] death 7/60 12/60 CORIPLASM Lacombe (RCT) 64% 0.36 [0.14-0.97] death 4/22 11/27 CORIPLASM Lacombe (RCT) -68% 1.68 [0.74-3.35] progression 13/60 8/60 CORIPLASM Lacombe (RCT) -4% 1.04 [0.61-1.78] progression 19/60 20/60 CORIPLASM Lacombe (RCT) -7% 1.07 [0.00-9700] hosp. time 60 (n) 60 (n) CCAP-2 Thorlaci.. (DB RCT) -76% 1.76 [0.62-5.01] death 15/98 4/46 CCAP-2 Thorlaci.. (DB RCT) -88% 1.88 [0.56-6.33] death 12/98 3/46 CCAP-2 Thorlaci.. (DB RCT) -72% 1.72 [0.50-5.87] death 11/98 3/46 CCAP-2 Thorlaci.. (DB RCT) -64% 1.64 [0.36-7.60] death 7/98 2/46 CCAP-2 Thorlaci.. (DB RCT) -735% 8.35 [0.47-148] death 5/98 0/46 CCAP-2 Thorlaci.. (DB RCT) -37% 1.37 [0.29-6.52] ventilation 6/94 2/43 CCAP-2 Thorlaci.. (DB RCT) -31% 1.31 [0.45-3.82] ICU 12/89 4/39 CCAP-2 Thorlaci.. (DB RCT) -41% 1.41 [0.72-2.09] 7-point status 98 (n) 46 (n) PLACO COVID Manzini (DB RCT) -25% 1.25 [0.61-2.57] death 14/60 12/60 PLACO COVID Manzini (DB RCT) -10% 1.10 [0.61-1.95] death/int. 17/59 14/56 PLACO COVID Manzini (DB RCT) -6% 1.06 [0.70-1.61] viral time 60 (n) 60 (n) PassItOn Self (DB RCT) -3% 1.03 [0.73-1.44] death 89/482 80/465 PassItOn Self (DB RCT) -26% 1.26 [0.81-1.90] death 63/482 48/465 PassItOn Self (DB RCT) -4% 1.04 [0.82-1.33] 7-point status 487 (n) 473 (n) REMAP-CAP Higgins (RCT) 1% 0.99 [0.86-1.14] death 370/944 324/790 ICU patients Denkinger (RCT) 8% 0.92 [0.75-1.11] death 68 (n) 66 (n) Denkinger (RCT) -2% 1.02 [0.59-1.77] ventilation 19/68 18/66 Denkinger (RCT) 22% 0.78 [0.52-1.16] 7-point status 68 (n) 66 (n) Baksh (DB RCT) -1% 1.01 [0.94-1.09] no recov. 381/538 381/532 Baksh (DB RCT) -4% 1.04 [0.79-1.39] PASC 533 (n) 528 (n) Baksh (DB RCT) 9% 0.91 [0.60-1.37] PASC 232 (n) 234 (n) Baksh (DB RCT) -18% 1.18 [0.80-1.74] PASC 301 (n) 294 (n) Alshamrani (PSM) -14% 1.14 [0.79-1.45] death 24/41 108/205 Alshamrani (PSM) -17% 1.17 [0.93-1.28] progression 34/41 154/205 Alshamrani (PSM) -43% 1.43 [1.13-1.80] ICU 37 (n) 166 (n) Alshamrani (PSM) -32% 1.32 [1.07-1.63] hosp. time 41 (n) 205 (n) Krishnan -270% 3.70 [0.90-15.8] death case control Kasten -4% 1.04 [0.49-2.21] death 7/19 11/31 Kasten -17% 1.17 [0.43-3.15] death 5/19 7/31 Co-CLARITY Gauiran (RCT) -400% 5.00 [0.25-98.5] death 2/22 0/22 Co-CLARITY Gauiran (RCT) -100% 2.00 [0.20-20.5] ICU 2/22 1/22 Co-CLARITY Gauiran (RCT) -7% 1.07 [0.77-1.50] hosp. time 22 (n) 22 (n) Lewandowski -62% 1.62 [0.88-2.98] death 430 (all patients) CP_COVID-19 Khawaja (DB RCT) -154% 2.54 [0.11-59.6] death 1/37 0/20 CP_COVID-19 Khawaja (DB RCT) 73% 0.27 [0.03-2.80] ventilation 1/37 2/20 CP_COVID-19 Khawaja (DB RCT) 46% 0.54 [0.12-2.43] ICU 3/37 3/20 Iasella (PSM) -26% 1.26 [0.93-1.71] death 73/290 58/290 Iasella (PSM) -1% 1.01 [0.86-1.17] ventilation 155/290 154/290 Iasella (PSM) 0% 1.00 [0.82-1.22] progression 118/290 118/290 Shaheen (RCT) 0% 1.00 [0.43-2.31] death 8/30 8/30 Convalescent plasma COVID-19 outcomes c19early.org June 2025 ​1​ OT: comparison with other treatment Favors conv. plasma Favors control
Figure S1. All outcomes.
Loading..
Figure S2. Comparison of results for RCTs versus observational studies. For COVID-19 treatments, there is no significant difference between the results of RCTs and observational studies. Observational studies do not systematically over or underestimate efficacy. For high-cost treatments, there is a non-significant trend towards RCTs showing greater efficacy.
Please send us corrections, updates, or comments. c19early involves the extraction of 200,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. IMA and WCH provide treatment protocols.
  or use drag and drop   
Submit    
Post
Share
@CovidAnalysis
FAQ
Public domain CC0 1.0